BIOMAT Database Logo BIOMAT Database Logo

Pharmacodynamics of daily subcutaneous recombinant human interleukin-3 in normal volunteers. 1995

R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Program in Clinical Pharmacology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick 08903-0019.

Normal volunteers received subcutaneous injections of recombinant human interleukin-3 (rhIL-3) on 4 consecutive days to characterize toxicity, pharmacokinetics, and hematopoietic effects. Dosages were 2.5, 5.0, and 7.5 micrograms/kg/day (n = 6 subjects per group). Adverse effects consisted predominantly of flu-like symptoms such as fever and headache. Mean area under the serum concentration-time curve and maximum serum concentration were linearly related to dose. Serum clearance was not apparently related to dose. Clearance increased slightly but significantly between days 1 and 4. Rapid but modest elevations in neutrophil and eosinophil counts were observed during treatment. Mean platelet counts rose modestly, peaking on day 10. Increases of CD34+ cell counts were correlated with increases of colony-forming unit-granulocyte macrophage (peak, day 7).

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007377 Interleukin-3 A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. Burst-Promoting Factor, Erythrocyte,Colony-Stimulating Factor 2 Alpha,Colony-Stimulating Factor, Mast-Cell,Colony-Stimulating Factor, Multipotential,Erythrocyte Burst-Promoting Factor,IL-3,Mast-Cell Colony-Stimulating Factor,Multipotential Colony-Stimulating Factor,P-Cell Stimulating Factor,Eosinophil-Mast Cell Growth-Factor,Hematopoietin-2,Burst Promoting Factor, Erythrocyte,Colony Stimulating Factor, Mast Cell,Colony Stimulating Factor, Multipotential,Eosinophil Mast Cell Growth Factor,Erythrocyte Burst Promoting Factor,Hematopoietin 2,Interleukin 3,Multipotential Colony Stimulating Factor,P Cell Stimulating Factor
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006261 Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS. Cephalgia,Hemicrania,Bilateral Headache,Cephalalgia,Cephalodynia,Cranial Pain,Generalized Headache,Head Pain,Ocular Headache,Orthostatic Headache,Periorbital Headache,Retro-Ocular Headache,Sharp Headache,Throbbing Headache,Unilateral Headache,Vertex Headache,Bilateral Headaches,Cephalalgias,Cephalgias,Cephalodynias,Cranial Pains,Generalized Headaches,Head Pains,Headache, Bilateral,Headache, Generalized,Headache, Ocular,Headache, Orthostatic,Headache, Periorbital,Headache, Retro-Ocular,Headache, Sharp,Headache, Throbbing,Headache, Unilateral,Headache, Vertex,Headaches,Headaches, Bilateral,Headaches, Generalized,Headaches, Ocular,Headaches, Orthostatic,Headaches, Periorbital,Headaches, Retro-Ocular,Headaches, Sharp,Headaches, Throbbing,Headaches, Unilateral,Headaches, Vertex,Ocular Headaches,Orthostatic Headaches,Pain, Cranial,Pain, Head,Pains, Cranial,Pains, Head,Periorbital Headaches,Retro Ocular Headache,Retro-Ocular Headaches,Sharp Headaches,Throbbing Headaches,Unilateral Headaches,Vertex Headaches
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis

Related Publications

R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers.
August 1997, Clinical pharmacology and therapeutics,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys.
January 2010, Pharmacology,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
October 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Recombinant human interleukin-3 induces extramedullary hematopoiesis at subcutaneous injection sites in cynomolgus monkeys.
January 1996, Toxicologic pathology,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers.
February 2012, Basic & clinical pharmacology & toxicology,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Immunogenicity of recombinant human interleukin-3.
April 1997, Clinical immunology and immunopathology,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects.
April 2000, Cytokine,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Pharmacokinetics and pharmacodynamics of recombinant human interleukin-12 in male rhesus monkeys.
July 1995, The Journal of pharmacology and experimental therapeutics,
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Recombinant human interleukin 3 in clinical oncology.
March 1993, Stem cells (Dayton, Ohio),
R D Huhn, and E J Yurkow, and J G Kuhn, and L Clarke, and H Gunn, and D Resta, and R Shah, and L A Myers, and J R Seibold
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
July 1992, British journal of cancer,
Copied contents to your clipboard!